Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 19, 2026, 9:09 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 253 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Febrile Infection Clear all
Enrolling by invitation No phase listed Observational

Analysis of the Virtual Acute Care at Home Experience

NCT05952999
View directory record Official record
Conditions
Conditions, Infections, Heart Failure, Renal and Urinary Disorders, Diabetes, Hypertension, Fever, Bronchitis, Asthma, Chronic Obstructive Pulmonary Disease (COPD)
Interventions
Digital Care Solution as supportive personalized care, Traditional Hospital Level Care
Other
Lead sponsor
OSF Healthcare System
Other
Eligibility
18 Years and older
Enrollment
9,654 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2026
U.S. locations
1
States / cities
Peoria, Illinois
Source: ClinicalTrials.gov public record
Updated Mar 17, 2026 · Synced Oct 19, 2026, 9:09 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Evaluation of the Safety and Immune Response to an Investigational Dengue Type 1 Vaccine

NCT01084291
View directory record Official record
Conditions
Dengue Virus
Interventions
Investigational Vaccine for DEN1, Placebo injection
Biological · Other
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years to 50 Years
Enrollment
18 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2010
U.S. locations
2
States / cities
Burlington, Vermont
Source: ClinicalTrials.gov public record
Updated Jan 3, 2013 · Synced Oct 19, 2026, 9:09 AM EDT
Terminated Phase 3 Interventional Results available

Study Evaluating The Efficacy Of A Novel Ibuprofen Formulation On Fever In Patients With An Uncomplicated Acute Infection

NCT01035346
View directory record Official record
Conditions
Infection
Interventions
Ibuprofen, Placebo
Drug
Lead sponsor
Pfizer
Industry
Eligibility
12 Years to 65 Years
Enrollment
16 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2011
U.S. locations
5
States / cities
Cypress, California • Westlake Village, California • Omaha, Nebraska + 2 more
Source: ClinicalTrials.gov public record
Updated Aug 21, 2012 · Synced Oct 19, 2026, 9:09 AM EDT
Completed No phase listed Observational

Natural History of West Nile Virus Infection

NCT00069303
View directory record Official record
Conditions
West Nile Virus, Encephalitis, Myelitis
Interventions
Not listed
Lead sponsor
National Institutes of Health Clinical Center (CC)
NIH
Eligibility
18 Years and older
Enrollment
110 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2011
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Jul 2, 2017 · Synced Oct 19, 2026, 9:09 AM EDT
Completed Phase 3 Interventional Accepts healthy volunteers Results available

Long-Term Safety and Antibody Persistence of TDV and the Impact of a Booster Dose

NCT03999996
View directory record Official record
Conditions
Dengue Fever
Interventions
Takeda's Dengue Tetravalent Vaccine (Live, Attenuated) (TDV), Placebo
Biological
Lead sponsor
Takeda
Industry
Eligibility
13 Years to 63 Years
Enrollment
365 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2024
U.S. locations
8
States / cities
Huntsville, Alabama • Peoria, Illinois • Newton, Kansas + 5 more
Source: ClinicalTrials.gov public record
Updated Jul 30, 2026 · Synced Oct 19, 2026, 9:09 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Evaluation of the Safety and the Ability of a DNA Vaccine to Protect Against Dengue Disease

NCT01502358
View directory record Official record
Conditions
Dengue Disease, Dengue Fever
Interventions
Tetravalent Dengue Vaccine (TVDV), Tetravalent Dengue Vaccine (TVDV) with Vaxfectin® (low-dose), Tetravalent Dengue Vaccine TVDV with Vaxfectin® (High Dose)
Biological
Lead sponsor
U.S. Army Medical Research and Development Command
Federal
Eligibility
18 Years to 50 Years
Enrollment
40 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2011 – 2013
U.S. locations
1
States / cities
Silver Spring, Maryland
Source: ClinicalTrials.gov public record
Updated Nov 4, 2016 · Synced Oct 19, 2026, 9:09 AM EDT
Completed Not applicable Interventional

Efficacy of Surgical Diathermy in Eradicating Cutibacterium Acnes From Surgical Skin Incision During Shoulder Arthroplasty

NCT04608916
View directory record Official record
Conditions
Infection, Bacterial
Interventions
Using surgical diathermy to make skin incision, Using scalpel blade to make skin incision
Procedure
Lead sponsor
University of Missouri-Columbia
Other
Eligibility
18 Years and older · Male only
Enrollment
64 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2022
U.S. locations
1
States / cities
Columbia, Missouri
Source: ClinicalTrials.gov public record
Updated Apr 11, 2023 · Synced Oct 19, 2026, 9:09 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Safety of and Immune Response to Two Different Dengue Virus Vaccines in Individuals Previously Immunized Against Dengue Virus

NCT00458120
View directory record Official record
Conditions
Dengue Hemorrhagic Fever
Interventions
rDEN1delta30, rDEN2/4delta30(ME), Placebo to rDEN1delta30 or rDEN2/4delta30(ME)
Biological
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years to 50 Years
Enrollment
36 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2007 – 2008
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Dec 14, 2010 · Synced Oct 19, 2026, 9:09 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Evaluating the Safety and Protective Efficacy of a Single Dose of the Live Attenuated Tetravalent Dengue Vaccine TV005 to Protect Against Infection With rDEN3Δ30

NCT02873260
View directory record Official record
Conditions
Dengue
Interventions
TetraVax-DV-TV005, rDEN3Δ30, Placebo
Biological
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years to 50 Years
Enrollment
48 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016 – 2017
U.S. locations
2
States / cities
Baltimore, Maryland • Burlington, Vermont
Source: ClinicalTrials.gov public record
Updated Mar 8, 2018 · Synced Oct 19, 2026, 9:09 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

Chikungunya Virus Vaccine Trial in Healthy Adults

NCT01489358
View directory record Official record
Conditions
Viral Vaccines, Chikungunya Fever, Chikungunya Virus Infection
Interventions
VRC-CHKVLP059-00-VP
Biological
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years to 50 Years
Enrollment
25 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2011 – 2013
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Jul 25, 2016 · Synced Oct 19, 2026, 9:09 AM EDT
Withdrawn Phase 1 Interventional

Recombinant Human Mannose-Binding Lectin (MBL) in Treating Young Patients With MBL Deficiency and Fever and Neutropenia

NCT00886496
View directory record Official record
Conditions
Fever, Sweats, and Hot Flashes, Infection, Leukemia, Lymphoma, Myelodysplastic Syndromes, Neutropenia, Unspecified Childhood Solid Tumor, Protocol Specific
Interventions
recombinant human mannose-binding lectin
Biological
Lead sponsor
Enzon Pharmaceuticals, Inc.
Industry
Eligibility
2 Years to 17 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2011
U.S. locations
3
States / cities
Orange, California • Washington D.C., District of Columbia • Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jun 20, 2012 · Synced Oct 19, 2026, 9:09 AM EDT
Completed No phase listed Observational

West Nile Virus Natural History

NCT00138463
View directory record Official record
Conditions
West Nile Virus
Interventions
Not listed
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years and older
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2008
U.S. locations
27
States / cities
Birmingham, Alabama • Mobile, Alabama • Phoenix, Arizona + 23 more
Source: ClinicalTrials.gov public record
Updated Nov 7, 2011 · Synced Oct 19, 2026, 9:09 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Evaluation of the Safety and Immunogenicity of rDEN3Δ30, a Live Attenuated Monovalent Dengue Virus Vaccine

NCT02684383
View directory record Official record
Conditions
Dengue
Interventions
rDEN3∆30, Placebo
Biological
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years to 50 Years
Enrollment
14 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
Ends 2016
U.S. locations
2
States / cities
Baltimore, Maryland • Burlington, Vermont
Source: ClinicalTrials.gov public record
Updated Nov 30, 2016 · Synced Oct 19, 2026, 9:09 AM EDT
Completed Phase 1 Interventional

Poly-ICLC to Prevent Respiratory Viral Infections A Safety Study

NCT00646152
View directory record Official record
Conditions
Influenza, Severe Acute Respiratory Distress Syndrome, Smallpox, Ebola, Unknown Respiratory Viruses
Interventions
Poly-ICLC
Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years to 70 Years
Enrollment
57 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2009
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Jul 5, 2018 · Synced Oct 19, 2026, 9:09 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

Safety and Immunogenicity Study of a Dengue Virus DNA Vaccine

NCT00290147
View directory record Official record
Conditions
Dengue
Interventions
D1ME100 (dengue-1 premembrane/envelope DNA vaccine)
Biological
Lead sponsor
U.S. Army Medical Research and Development Command
Federal
Eligibility
18 Years to 50 Years
Enrollment
22 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2006 – 2009
U.S. locations
1
States / cities
Silver Spring, Maryland
Source: ClinicalTrials.gov public record
Updated Jun 20, 2017 · Synced Oct 19, 2026, 9:09 AM EDT
Completed Phase 3 Interventional

Phase 3 Efficacy and Safety Study of Favipiravir for Treatment of Uncomplicated Influenza in Adults - T705US316

NCT02026349
View directory record Official record
Conditions
Influenza
Interventions
favipiravir, Placebo
Drug
Lead sponsor
MDVI, LLC
Industry
Eligibility
18 Years to 80 Years
Enrollment
860 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2015
U.S. locations
60
States / cities
Birmingham, Alabama • Hunstville, Alabama • Hot Springs, Arkansas + 48 more
Source: ClinicalTrials.gov public record
Updated Nov 11, 2015 · Synced Oct 19, 2026, 9:09 AM EDT
Completed Phase 4 Interventional Results available

Pharmacokinetic/Pharmacodynamic Study of Doripenem in Febrile Neutropenic Patients

NCT01401010
View directory record Official record
Conditions
Febrile Neutropenia
Interventions
doripenem
Drug
Lead sponsor
Gary E. Stein, Pharm.D.
Other
Eligibility
18 Years and older
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2012
U.S. locations
1
States / cities
Lansing, Michigan
Source: ClinicalTrials.gov public record
Updated Oct 14, 2015 · Synced Oct 19, 2026, 9:09 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Safety Study of a Vaccine (DENV-1 PIV) to Prevent Dengue Disease

NCT01502735
View directory record Official record
Conditions
Dengue Fever
Interventions
DENV-1 PIV, 2.5 µg, DENV-1 PIV, 5 µg
Biological
Lead sponsor
U.S. Army Medical Research and Development Command
Federal
Eligibility
18 Years to 50 Years
Enrollment
20 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2011 – 2013
U.S. locations
1
States / cities
Silver Spring, Maryland
Source: ClinicalTrials.gov public record
Updated Apr 22, 2015 · Synced Oct 19, 2026, 9:09 AM EDT
Recruiting No phase listed Observational

Diagnosis and Management of Inflammatory and Infectious Diseases

NCT00557726
View directory record Official record
Conditions
Infection, Inflammation
Interventions
Not listed
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
3 Years to 100 Years
Enrollment
400 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 1978
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Oct 16, 2026 · Synced Oct 19, 2026, 9:09 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Evaluation of the Efficacy of the Live Attenuated Tetravalent Dengue Vaccine Against DENV-2 and DENV-3 Challenge

NCT03416036
View directory record Official record
Conditions
Dengue
Interventions
TetraVax-DV-TV003 (TV003), rDEN2Δ30-7169 (DENV-2), rDEN3Δ30 (DENV-3), Placebo
Biological
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years to 50 Years
Enrollment
64 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017 – 2019
U.S. locations
2
States / cities
Baltimore, Maryland • Burlington, Vermont
Source: ClinicalTrials.gov public record
Updated Jan 18, 2020 · Synced Oct 19, 2026, 9:09 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Evaluating the Safety and Protective Efficacy of a Single Dose of a Trivalent Live Attenuated Dengue Vaccine to Protect Against Infection With DENV-2

NCT02433652
View directory record Official record
Conditions
Dengue
Interventions
Recombinant live attenuated trivalent dengue vaccine, Placebo, rDEN2Δ30-7169 vaccine
Biological
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years to 50 Years
Enrollment
24 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
Started 2015
U.S. locations
2
States / cities
Baltimore, Maryland • Burlington, Vermont
Source: ClinicalTrials.gov public record
Updated Feb 28, 2018 · Synced Oct 19, 2026, 9:09 AM EDT
Recruiting Not applicable Interventional

Sauna for Long Covid

NCT05931497
View directory record Official record
Conditions
Long COVID
Interventions
whole body hyperthermia
Device
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
18 Years to 65 Years
Enrollment
21 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Nov 13, 2025 · Synced Oct 19, 2026, 9:09 AM EDT
Active, not recruiting Early Phase 1 Interventional Accepts healthy volunteers

Induction of Gut Permeability by an Oral Vaccine

NCT04083950
View directory record Official record
Conditions
Intestinal Permeability, Inflammation, Vaccine, Typhoid Fever
Interventions
Vivotif Typhoid Oral Vaccine, Aspirin (Positive Control)
Biological · Drug
Lead sponsor
USDA, Western Human Nutrition Research Center
Federal
Eligibility
18 Years to 49 Years · Female only
Enrollment
10 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2026
U.S. locations
1
States / cities
Davis, California
Source: ClinicalTrials.gov public record
Updated Nov 24, 2025 · Synced Oct 19, 2026, 9:09 AM EDT
Completed Phase 2 Interventional Results available

Comparative Study To Determine The Efficacy, Safety, And Tolerability Of Ceftolozane-Tazobactam

NCT03485950
View directory record Official record
Conditions
Other Infectious Diseases
Interventions
Cefepime, Ceftolozane, Laboratory Biomarker Analysis, Meropenem, Piperacillin-Tazobactam, Tazobactam
Drug · Other
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2022
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Mar 15, 2022 · Synced Oct 19, 2026, 9:09 AM EDT